In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Making the Most of Incremental Advantages in the Hepatitis C Market

Executive Summary

Schering-Plough's largest drug--a combination of PEG-INTRON (peginterferon alfa-2b) and Rebetol (ribavirin) for hepatitis C--has enjoyed an enormous and growing market to itself. Now, though, Roche is about to challenge Schering-Ploughy's hegemony. Roche has fired the first volley in a battle that will be based as much on marketing as on clinical features and benefits; it has priced its ribavirin at 43% below that of SGP's version.
Advertisement

Related Content

Hep C Development Dilemma: Big Money Now or Bigger Money Later?
Hep C Development Dilemma: Big Money Now or Bigger Money Later?
Enzon and NPS: One Brings the Bread, the Other Brings Wine
Enzon and NPS: One Brings the Bread, the Other Brings Wine
The Heat is on for First Circle Medical

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel